Cargando…
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab. Methods: A retrospective pharmacovigilance study was conduct...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467285/ https://www.ncbi.nlm.nih.gov/pubmed/37654615 http://dx.doi.org/10.3389/fphar.2023.1229304 |